Squarepoint
ACAD icon

Squarepoint’s Acadia Pharmaceuticals ACAD Stock Holding History

Squarepoint’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,500
Closed -$274K – 4424
2025
Q1 		$274K Buy
+16,500
New +$300K ﹤0.01% 3802
2024
Q2 		– Sell
-20,200
Closed -$373K – 3984
2024
Q1 		$373K Buy
+20,200
New +$500K ﹤0.01% 3245

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Squarepoint's ACAD Position: Q1 2026 in Review

Squarepoint increased its Acadia Pharmaceuticals (ACAD) stake by 810% in Q1 2026, buying an estimated $7.88M and bringing the position to 370,458 shares worth $8.25M. The position accounts for 0.01% of the portfolio, ranked #1180.

Squarepoint first reported a position in ACAD in Q4 2015 and has held it in 29 quarters since. The position peaked at $18.7M in Q1 2024. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Squarepoint held 370,458 shares of Acadia Pharmaceuticals worth $8.25M as of Q1 2026.
  • Squarepoint bought 329,749 Acadia Pharmaceuticals shares in Q1 2026, an estimated $7.88M.
  • Acadia Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1180 holding.
  • Squarepoint first reported a position in Acadia Pharmaceuticals in Q4 2015 and has held it in 29 quarters since.
  • Squarepoint's Acadia Pharmaceuticals position peaked at $18.7M in Q1 2024.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.